A Phase II Study of Weekly Paclitaxel, Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(Weekly TP-HDFL) in the Treatment of Advanced Transitional Cell Carcinoma(TCC)
Transitional cell carcinoma(TCC)of urothelium,including bladder, ureter, and renal pelvis
TCCs, was the most lethal urology malignancy in Taiwan. In 1995, approximately 1,300 new
cases of TCC was diagnosed in Taiwan and more than 600 patients died of this disease.
Advanced TCC is a moderately chemosensitive disease. A combination of methotrexate,
vinblastine, and cisplatin with or without doxorubicin (M-VAC or CMV) has been widely used
since 1980s. Despite the response rate was as high as 40-70%, the survival of these patients
was only slightly increased from a median of 7 to 9 months for those who were treated with
supportive care or cisplatin alone to a median of 12 months by cisplatin-based combination
chemotherapy. One of the reasons for the poor treatment results is the inevitable
treatment-related toxicities related to conventional systemic chemotherapy.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Chih-Hung Hsu, M.D.,Ph.D.
Department of Oncology , National Taiwan University Hospital
Taiwan: Department of Health